Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waxman to seek Medicaid prices for dual eligbles

Executive Summary

Legislation that would set Medicare Part D drug prices paid specifically for dual eligible beneficiaries at rates that were paid under Medicaid prior to being shifted to the federal prescription drug program is under development by House Oversight and Government Reform Committee Chairman Henry Waxman, D-Calif. The pending bill is an outgrowth of a report the committee released in July that said the government is paying 30 percent more for dual eligibles' drugs since drug coverage for the dual eligibles shifted from Medicaid to Medicare Part D under the Medicare Modernization Act (1"The Pink Sheet," July 28, 2008, p. 24). Brian Cohen, senior investigative counsel for the committee, said Sept. 23 during the AHIP annual Medicare and Medicaid conference that a bill could be introduced soon, but at the very latest early into the next Congress

You may also be interested in...



CBO Scores 15% Rebate For All Part D Brand Drugs In Health Care Report

The Congressional Budget Office has taken proposals for a required rebate on drugs for dual-eligible beneficiaries in Medicare Part D a step further by scoring a 15 percent rebate requirement for all brand drugs in the program

Republican Strategy To Protect Part D Raises Risks For Pharma

House Oversight and Government Reform Committee Republicans are attempting to deflect criticism of Medicare Part D drug expenditures by redirecting focus back to larger expenditures under Parts A and B

Patient Voice Makes Impact In Scientific Advice From EU HTA Network

The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.

UsernamePublicRestriction

Register

PS050162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel